Cerebrospinal fluid (CSF) amyloid-β (Aβ) 42 and tau are biomarkers for Alzheimer's disease
(AD); however, the effects of other neurodegenerative processes on these biomarkers …

Cerebral hypometabolism and abnormal levels of amyloid beta (Aβ), total (t-tau) and
phosphorylated tau (ptau) proteins in cerebrospinal fluid (CSF) are established biomarkers …

Background and Objective Individuals with biomarker evidence of β-amyloid (Aβ) deposition
are increasingly being enrolled in clinical treatment trials but there is a need to identify …

Cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ) 1-38, 1-40, 1-42, total-tau and
phospho-tau in samples from 156 patients with Alzheimer's disease (AD)(n= 44), depressive …

This study evaluated the sensitivity and specificity of the cerebrospinal fluid (CSF) levels of
tau-protein, amyloid-ß-peptide 1-42 (Aß1-42), ApoE-genotype and the degree of cognitive …

Introduction The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's
disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias …

We recently demonstrated that the frequencies of biomarker groups defined by the presence
or absence of both amyloidosis (A+) and neurodegeneration (N+) changed dramatically by …

Background We previously identified four Alzheimer's disease (AD) subgroups with
increasingly higher cerebrospinal fluid (CSF) levels of tau phosphorylated at threonine 181 …

The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring
the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) …

Background We recently reported that CSF phosphorylated tau (p-Tau 181) relative to Aβ 40
(CSF p-Tau/Aβ 40 ratio) was less noisy and increased associations with Alzheimer's disease …